Yang Wei Tse, Lane Deanna L, Le-Petross Huong T, Abruzzo Lynne V, Macapinlac Homer A
Department of Diagnostic Radiology, University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1350, Houston, TX 77030, USA.
Radiology. 2007 Dec;245(3):692-702. doi: 10.1148/radiol.2452061726. Epub 2007 Oct 2.
To retrospectively evaluate the imaging findings of breast lymphomas in patients who had undergone mammography, ultrasonography (US), magnetic resonance (MR) imaging, or combined positron emission tomography (PET)/computed tomography (CT) scanning.
The institutional review board approved this HIPAA-compliant study and waived informed consent. Twenty-seven women who had been diagnosed with breast lymphoma (32 tumors) and had undergone preoperative imaging were identified from the surgical pathology database (mean age, 51 years; median, 55 years; range, 19-78 years at time of diagnosis). Two radiologists reviewed the mammographic, US, and MR images. One nuclear medicine physician reviewed the PET/CT scans. All available pathologic specimens were reviewed by a hematologic pathologist.
The mean tumor size at diagnosis was 2.9 cm (range, 1-5 cm). Seventeen tumors manifested with a palpable mass, two with diffuse enlargement of the breast, and 13 were asymptomatic. Twenty-two women underwent mammography; 24, US; one, MR imaging; and 10, PET/CT scanning. Mammograms of 25 tumors showed a noncalcified mass in 19, global asymmetry in four, focal asymmetry in one, and no abnormality in one. US of 29 tumors showed a mass in 26 and diffuse architectural distortion in three. Masses typically were irregular, hypoechoic, and hypervascular and demonstrated indistinct margins or an echogenic boundary. Dynamic contrast material-enhanced MR imaging of one tumor showed an intensely and heterogeneously enhancing mass with rapid enhancement and washout characteristics. PET/CT scans of 13 tumors showed intense diffuse hypermetabolism in 12 and response to therapy in all 12 tumors.
The imaging findings reported in this study should alert the radiologist to a possible diagnosis of breast lymphoma.
回顾性评估接受过乳腺钼靶摄影、超声(US)、磁共振(MR)成像或正电子发射断层扫描(PET)/计算机断层扫描(CT)联合扫描的乳腺淋巴瘤患者的影像学表现。
机构审查委员会批准了这项符合健康保险流通与责任法案(HIPAA)的研究,并豁免了知情同意。从手术病理数据库中识别出27例被诊断为乳腺淋巴瘤(32个肿瘤)且接受过术前影像学检查的女性患者(诊断时平均年龄51岁;中位数55岁;范围19 - 78岁)。两名放射科医生对乳腺钼靶、超声和MR图像进行了回顾。一名核医学医生对PET/CT扫描进行了回顾。所有可用的病理标本均由血液病理学家进行了审查。
诊断时肿瘤平均大小为2.9厘米(范围1 - 5厘米)。17个肿瘤表现为可触及肿块,2个表现为乳腺弥漫性增大,13个无症状。22名女性接受了乳腺钼靶摄影;24名接受了超声检查;1名接受了MR成像;10名接受了PET/CT扫描。25个肿瘤的乳腺钼靶片显示19个为非钙化肿块,4个为整体不对称,1个为局灶性不对称,1个无异常。29个肿瘤的超声检查显示26个为肿块,3个为弥漫性结构扭曲。肿块通常不规则、低回声且血管丰富,边缘不清或有回声边界。1个肿瘤的动态对比剂增强MR成像显示为强化强烈且不均匀的肿块,具有快速强化和廓清特征。13个肿瘤的PET/CT扫描显示12个有强烈的弥漫性高代谢,且所有12个肿瘤对治疗有反应。
本研究报告的影像学表现应提醒放射科医生注意乳腺淋巴瘤的可能诊断。